| 368845 |
PDL1Atezolizumab2_model3 |
MM/GBSA |
Completed |
2026-04-20 20:12:42 (UTC + 8 hours) |
| 368844 |
PDL1Atezolizumab2_model2 |
MM/GBSA |
Completed |
2026-04-20 20:12:42 (UTC + 8 hours) |
| 368843 |
PDL1Atezolizumab2_model1 |
MM/GBSA |
Completed |
2026-04-20 20:12:42 (UTC + 8 hours) |
| 368842 |
ID501238 |
MM/GBSA |
Completed |
2026-04-20 20:11:15 (UTC + 8 hours) |
| 368841 |
ID718094 |
MM/GBSA |
Completed |
2026-04-20 20:07:18 (UTC + 8 hours) |
| 368840 |
ID982695 |
MM/GBSA |
Completed |
2026-04-20 20:03:42 (UTC + 8 hours) |
| 368839 |
ID611335 |
MM/GBSA |
Completed |
2026-04-20 19:59:39 (UTC + 8 hours) |
| 368838 |
ID379238 |
MM/GBSA |
Completed |
2026-04-20 19:55:56 (UTC + 8 hours) |
| 368837 |
nnexo3 |
MM/GBSA |
Completed |
2026-04-20 19:42:53 (UTC + 8 hours) |
| 368836 |
S89W |
MM/GBSA |
Completed |
2026-04-20 19:38:43 (UTC + 8 hours) |
| 368835 |
PDL1Atezolizumab2_model10 |
MM/GBSA |
Completed |
2026-04-20 19:38:33 (UTC + 8 hours) |
| 368834 |
PDL1Atezolizumab2_model9 |
MM/GBSA |
Completed |
2026-04-20 19:38:33 (UTC + 8 hours) |
| 368833 |
PDL1Atezolizumab2_model8 |
MM/GBSA |
Completed |
2026-04-20 19:38:33 (UTC + 8 hours) |
| 368832 |
PDL1Atezolizumab2_model7 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368831 |
PDL1Atezolizumab2_model6 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368830 |
PDL1Atezolizumab2_model5 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368829 |
PDL1Atezolizumab2_model4 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368828 |
PDL1Atezolizumab2_model3 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368827 |
PDL1Atezolizumab2_model2 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |
| 368826 |
PDL1Atezolizumab2_model1 |
MM/GBSA |
Completed |
2026-04-20 19:38:32 (UTC + 8 hours) |